No Data
No Data
JMP Maintains AN2 Therapeutics Stock With $5 Target
AN2 Therapeutics, Inc.: Promising Future With Strong Financial Health and Strategic Advancements
AN2 Therapeutics | 10-K: FY2024 Annual Report
AN2 Therapeutics Reports Q4 EPS (25c) Vs (57c) Last Year
AN2 Therapeutics | 8-K: AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
Express News | AN2 Therapeutics: Anticipated to Fund Operations Through 2027 Under Current Strategic Plan